(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 August 2017 (10.08.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/134302 A3

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 16/28* (2006.01)
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/EP2017/052545

(22) International Filing Date:
6 February 2017 (06.02.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/291,769	5 February 2016 (05.02.2016)	US
62/291,772	5 February 2016 (05.02.2016)	US
62/291,774	5 February 2016 (05.02.2016)	US
62/291,776	5 February 2016 (05.02.2016)	US
62/291,779	5 February 2016 (05.02.2016)	US
62/335,880	13 May 2016 (13.05.2016)	US
62/335,965	13 May 2016 (13.05.2016)	US
62/335,968	13 May 2016 (13.05.2016)	US
62/335,979	13 May 2016 (13.05.2016)	US
62/336,030	13 May 2016 (13.05.2016)	US
62/353,607	23 June 2016 (23.06.2016)	US
62/411,805	24 October 2016 (24.10.2016)	US

(71) Applicants: **ORIONIS BIOSCIENCES NV** [BE/BE]; Rijvisschestraat 120, 9052 Zwijnaarde (BE). **VIB VZW** [BE/BE]; Rijvisschestraat 120, 9052 Gent (BE). **UNIVERSITEIT GENT** [BE/BE]; Sint-Pietersnieuwstraat 25, 9000 Gent (BE).

(72) Inventors: **TAVERNIER, Jan**; Bottelweg 2, B-9860 Balegem (BE). **KLEY, Nikolai**; c/o Orionis Biosciences, Inc., 275 Grove Street, Suite 2-400, Newton, MA 02466 (US).

(74) Agent: **GRUND INTELLECTUAL PROPERTY GROUP**; Nikolaistrasse 15, 80802 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) Title: TARGETED THERAPEUTIC AGENTS AND USES THEREOF

FIG. 5



(57) Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.

WO 2017/134302 A3

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
28 September 2017

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/052545

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/00 C07K16/24 C07K16/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, Sequence Search, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015/018528 A1 (CYTUNE PHARMA [FR]; UNIV PARIS DESCARTES [FR]; ASSIST PUBL HOPITAUX DE) 12 February 2015 (2015-02-12) page 9 - page 21	1,2,5-8, 10-14, 90,93, 94,97,98
X	US 2013/230517 A1 (GREWAL IQBAL [US] ET AL) 5 September 2013 (2013-09-05) abstract; table 1	1-18, 90-98

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 June 2017	30/08/2017

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Scheffzyk, Irmgard

8

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANDY J. MINN: "Interferons and the Immunogenic Effects of Cancer Therapy", TRENDS IN IMMUNOLOGY, vol. 36, no. 11, 1 November 2015 (2015-11-01), pages 725-737, XP055360461, GB ISSN: 1471-4906, DOI: 10.1016/j.it.2015.09.007 page 730	1-18, 90-98
A	LAURENCE ZITVOGEL ET AL: "Type I interferons in anticancer immunity", THE JOURNAL OF IMMUNOLOGY, vol. 15, no. 7, 1 June 2015 (2015-06-01), pages 405-414, XP055360458, GB ISSN: 1474-1733, DOI: 10.1038/nri3845 the whole document	1-18, 90-98

8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2017/052545

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

15-18(completely); 1-14, 90-98(partially)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 15-18(completely); 1-14, 90-98(partially)

   Chimeric protein according to claim 15
   ---

2. claims: 19-23(completely); 1-14, 90-98(partially)

   Chimeric protein acording to claim 19
   ---

3. claims: 24-31(completely); 1-14, 90-98(partially)

   Chimeric protein according to claim 24
   ---

4. claims: 46-49(completely); 32-45, 90-98(partially)

   Chimeric protein according to claim 46
   ---

5. claims: 50-54(completely); 32-45, 90-98(partially)

   Chimeric protein according to claim 50
   ---

6. claims: 55-62(completely); 32-45, 90-98(partially)

   Chimeric protein according to claim 55
   ---

7. claims: 77-81(completely); 63-76, 90-98(partially)

   Chimeric protein according to claim 77
   ---

8. claims: 82-89(completely); 63-76, 90-98(partially)

   Chimeric protein according to claim 82

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2017/052545

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015018528 A1	12-02-2015	AU 2014304931 A1	25-02-2016
		CA 2919725 A1	12-02-2015
		CN 105612175 A	25-05-2016
		EA 201690333 A1	30-06-2016
		EP 3030575 A1	15-06-2016
		JP 2016532693 A	20-10-2016
		KR 20160042922 A	20-04-2016
		US 2016175459 A1	23-06-2016
		WO 2015018528 A1	12-02-2015
US 2013230517 A1	05-09-2013	AU 2013230484 A1	12-02-2015
		CA 2866126 A1	12-09-2013
		CN 104470536 A	25-03-2015
		EP 2822575 A1	14-01-2015
		JP 2015515453 A	28-05-2015
		US 2013230517 A1	05-09-2013
		US 2015139951 A1	21-05-2015
		US 2017073388 A1	16-03-2017
		WO 2013134138 A1	12-09-2013